title: Prevalence of and factors associated with glucosamine use in Canada.
abstract: OBJECTIVE
  Glucosamine is commonly used for the treatment of osteoarthritis, and its use is increasing in the general population. The Canadian Multicentre Osteoporosis Study (CaMos) provided an opportunity to examine the prevalence of glucosamine use across age and gender groups, and to assess the factors associated with its use.
  
  
  METHODS
  CaMos is a random, population-based sample of 9423 Canadians. Baseline assessments took place in 1996-1997 and the 5-year follow-up assessments in 2001-2002. The primary outcome of this analysis was glucosamine use at year 5. Prevalence estimates were age- and sex-standardized to the Canadian population. A number of factors potentially associated with glucosamine use were identified from the literature. Multivariable logistic regression was used to identify variables associated with glucosamine use.
  
  
  RESULTS
  At 5 years, complete data were available for 7652 of the original 9423 participants (81.2%). For men, glucosamine use increased from 0.9% to 4.7% (weighted values), and for women, it increased from 1.3% to 8.2%. Glucosamine use was higher among older participants, those living in western Canada, and those with arthritis, back pain, higher calcium intake from supplements, physical activity and prior glucosamine use.
  
  
  CONCLUSIONS
  Glucosamine use increased substantially over 5 years, and its use is associated with a number of factors. Some may use glucosamine to manage pain and symptoms of arthritis and back pain, while others use it as a preventive measure to maintain health.
authors.affiliation: Clinical Research Centre, Kingston General Hospital, Kingston, Ontario, Canada. hopmanw@kgh.kari.net
authors.forename: W M
authors.initials: WM
authors.lastname: Hopman
authors.forename: T E
authors.initials: TE
authors.lastname: Towheed
authors.forename: Y
authors.initials: Y
authors.lastname: Gao
authors.forename: C
authors.initials: C
authors.lastname: Berger
authors.forename: L
authors.initials: L
authors.lastname: Joseph
authors.forename: S A
authors.initials: SA
authors.lastname: Vik
authors.forename: D A
authors.initials: DA
authors.lastname: Hanley
authors.forename: J
authors.initials: J
authors.lastname: Carran
authors.forename: T
authors.initials: T
authors.lastname: Anastassiades
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002170:Canada; D000529:Complementary Therapies / Q000706:statistics & numerical data; D019587:Dietary Supplements / Q000706:statistics & numerical data*; D004363:Drug Utilization / Q000706:statistics & numerical data / Q000639:trends; D004522:Educational Status; D005260:Female; D005500:Follow-Up Studies; D005944:Glucosamine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy* / Q000517:prevention & control; D011446:Prospective Studies; D012737:Sex Factors
chemical_list: D005944:Glucosamine